Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.

BioMarin vs. Catalyst: A Decade of SG&A Trends

__timestampBioMarin Pharmaceutical Inc.Catalyst Pharmaceuticals, Inc.
Wednesday, January 1, 20143021560004473654
Thursday, January 1, 20154022710008597010
Friday, January 1, 20164765930007910260
Sunday, January 1, 20175543360007304399
Monday, January 1, 201860435300015875961
Tuesday, January 1, 201968092400036881187
Wednesday, January 1, 202073766900044233754
Friday, January 1, 202175937500049628000
Saturday, January 1, 202285400900058183000
Sunday, January 1, 2023937300000133710000
Monday, January 1, 20241009025000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: BioMarin vs. Catalyst Pharmaceuticals

In the competitive world of biotechnology, managing operational costs is crucial for sustained growth. Over the past decade, BioMarin Pharmaceutical Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. BioMarin, a leader in rare disease therapies, has seen its SG&A costs rise steadily, peaking at nearly 937 million in 2023, reflecting a strategic investment in expanding its market reach. In contrast, Catalyst Pharmaceuticals, known for its focus on rare neurological diseases, has maintained a more conservative approach, with SG&A expenses growing from a modest 4.5 million in 2014 to 134 million in 2023. This represents a staggering 2,889% increase, highlighting Catalyst's aggressive scaling efforts. As these companies navigate the complexities of the biotech landscape, their financial strategies offer valuable insights into the balance between growth and operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025